Published in Cancer Res on November 01, 1991
Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer (2000) 1.06
Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol (1996) 1.05
Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol (2013) 0.98
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol (1995) 0.97
Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer (1993) 0.93
Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia (2006) 0.93
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer (2014) 0.92
Current perspectives on camptothecins in cancer treatment. Br J Cancer (1996) 0.90
Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients. Br J Cancer (2008) 0.90
Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int (2007) 0.89
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer (1996) 0.89
Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol (2006) 0.88
DNA topoisomerase IIalpha and -beta expression in human ovarian cancer. Br J Cancer (1999) 0.86
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy? Br J Cancer (1997) 0.85
Oral topoisomerase 1 inhibitors in adult patients: present and future. Invest New Drugs (1999) 0.84
Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer (1992) 0.83
Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br J Cancer (1995) 0.82
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer (1998) 0.79
Topoisomerase I inhibitors and drug resistance. Cytotechnology (1998) 0.78
Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother Pharmacol (1994) 0.78
Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases. Br J Cancer (2000) 0.75
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther (2010) 3.42
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol (2000) 3.20
Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol (1996) 2.94
[Three patients with massive pulmonary embolism]. Ned Tijdschr Geneeskd (2001) 2.89
Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology (1999) 2.61
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
Cigarette smoking and human papillomavirus in patients with reported cervical cytological abnormality. BMJ (1993) 2.50
Neutral amino acid transport by membrane vesicles of Streptococcus cremoris is subject to regulation by internal pH. J Bacteriol (1987) 2.44
Elimination of uninformative variables for multivariate calibration. Anal Chem (1996) 2.30
Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet (1999) 2.27
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
[Decisions around the end of life on Intensive Care: making the transition from curative to palliative treatment]. Ned Tijdschr Geneeskd (2005) 2.08
Catecholamine dependency in a polytrauma patient: relative adrenal insufficiency? Intensive Care Med (2000) 2.04
[The significance of elevated troponin levels in the absence of acute cardiac ischaemia]. Ned Tijdschr Geneeskd (2005) 2.03
[Again new resuscitation guidelines (2006): justification, costs and potential confusion]. Ned Tijdschr Geneeskd (2007) 2.01
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res (1993) 1.99
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 1.92
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology (2001) 1.84
Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res (1993) 1.81
Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1987) 1.81
Transport of branched-chain amino acids in membrane vesicles of Streptococcus cremoris. J Bacteriol (1987) 1.72
Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections. Am J Pathol (1987) 1.71
Condition on arrival of transferred critically ill patients. Neth J Med (2000) 1.67
Organophosphorus pesticide poisoning: cases and developments. Neth J Med (2008) 1.67
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol (1992) 1.62
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol (2000) 1.62
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Malignant struma ovarii treated by ovariectomy, thyroidectomy, and 131I administration. Cancer (1987) 1.50
[Wait-and-see policy versus loop excision after two consecutive Pap-2 cervical smears: over time less surgery and an equivalent outcome; no substantial contribution to be expected from the detection of high risk human papillomavirus]. Ned Tijdschr Geneeskd (2003) 1.45
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer (1991) 1.44
Cerebral perfusion and metabolism in resuscitated patients with severe post-hypoxic encephalopathy. J Neurol Sci (2003) 1.44
Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology (2000) 1.44
Combination therapy with cisplatin: modulation of activity and tumour sensitivity. Clin Oncol (R Coll Radiol) (1992) 1.43
Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst (1995) 1.43
Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) (2003) 1.43
Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res (2000) 1.42
Large-amplitude spin dynamics driven by a THz pulse in resonance with an electromagnon. Science (2014) 1.41
5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer (1995) 1.40
[Hypothermia in patients with a high spinal cord lesion]. Ned Tijdschr Geneeskd (1997) 1.40
[18 years experience with mechanical ventilation in patients with Duchenne muscular dystrophy]. Ned Tijdschr Geneeskd (2007) 1.40
Endodermal sinus tumor of the ovary during pregnancy: a case report. Am J Obstet Gynecol (1991) 1.40
[Orthopnea: not always of cardiac origin]. Ned Tijdschr Geneeskd (1999) 1.40
[Good results with liver resection for colorectal liver metastases]. Ned Tijdschr Geneeskd (1995) 1.40
[Clinical reasoning and decision-making in practice. A patient with shortness of breath and hyponatraemia]. Ned Tijdschr Geneeskd (2005) 1.39
[Diagnostic image (4)(Bronchoalveolar lavage fluid)]. Ned Tijdschr Geneeskd (2000) 1.39
Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol (2002) 1.39
[Carboplatin in the treatment of ovarian carcinoma; as effective and less toxic in comparison with cisplatin]. Ned Tijdschr Geneeskd (1991) 1.38
[CBO guideline 'Bacterial meningitis']. Ned Tijdschr Geneeskd (2001) 1.38
Residual infrarenal aortic neck following endovascular and open aneurysm repair. Eur J Vasc Endovasc Surg (2012) 1.38
Malignant peritoneal mesothelioma in a 76-year-old woman with a history of asbestos fiber ingestion. Int J Gynecol Cancer (2004) 1.38
Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med (2000) 1.38
Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut (2002) 1.38
A 17-yr old boy with productive cough and progressive dyspnoea. Eur Respir J (2000) 1.37
The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev (2000) 1.37
Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med (1997) 1.35
The clinical trail of TRAIL. Eur J Cancer (2006) 1.35
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol (1987) 1.34
Review article: anthranoid laxatives and their potential carcinogenic effects. Aliment Pharmacol Ther (1999) 1.34
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1990) 1.33
Nanoscale spin reversal by non-local angular momentum transfer following ultrafast laser excitation in ferrimagnetic GdFeCo. Nat Mater (2013) 1.31
White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry (2007) 1.31
A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer (2012) 1.28
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol (1998) 1.28
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ (2013) 1.27
Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer (1992) 1.25
Cervical tissue shrinkage by formaldehyde fixation, paraffin wax embedding, section cutting and mounting. Virchows Arch A Pathol Anat Histopathol (1983) 1.23
Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am J Pathol (1999) 1.23
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res (1992) 1.21
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
Fatal haemorrhage from Dieulafoy's disease of the bronchus. Thorax (1999) 1.20
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer (2007) 1.19
ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol (1999) 1.17
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst (1989) 1.16
Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol (2009) 1.16
Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol (1989) 1.16
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol (1989) 1.16
Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol (2001) 1.16
Predictive value of human papillomavirus type for histological diagnosis of women with cervical cytological abnormalities. BMJ (1995) 1.16